EAM
ITCI

Erste Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Erste Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-23,400
Closed -$3.08M – 915
2025
Q1 		$3.08M Hold
23,400
– – 0.04% 261
2024
Q4 		$1.99M Hold
23,400
– – 0.02% 327
2024
Q3 		$1.72M Hold
23,400
– – 0.02% 341
2024
Q2 		$1.66M Hold
23,400
– – 0.02% 324
2024
Q1 		$1.63M Hold
23,400
– – 0.02% 326
2023
Q4 		$1.68M Hold
23,400
– – 0.02% 312
2023
Q3 		$1.26M Hold
23,400
– – 0.02% 322
2023
Q2 		$1.45M Hold
23,400
– – 0.03% 320
2023
Q1 		$1.31M Hold
23,400
– – 0.03% 320
2022
Q4 		$1.25M Hold
23,400
– – 0.03% 327
2022
Q3 		$1.06M Hold
23,400
– – 0.02% 350
2022
Q2 		$1.36M Hold
23,400
– – 0.03% 322
2022
Q1 		$1.41M Buy
23,400
+2,400
+11% +$125K 0.03% 328
2021
Q4 		$1.09M Hold
21,000
– – 0.02% 350
2021
Q3 		$752K Hold
21,000
– – 0.01% 364
2021
Q2 		$835K Hold
21,000
– – 0.02% 362
2021
Q1 		$683K Hold
21,000
– – 0.02% 362
2020
Q4 		$655K Hold
21,000
– – 0.02% 367
2020
Q3 		$536K Buy
+21,000
New +$479K 0.02% 347

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Erste Asset Management's ITCI Position: Q2 2025 in Review

Erste Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 23,400 shares — an estimated $3.08M sold.

Erste Asset Management first reported a position in ITCI in Q3 2020 and held it in 19 quarters. The position peaked at $3.08M in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Erste Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Erste Asset Management sold 23,400 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $3.08M.
  • Erste Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2020 and held it in 19 quarters.
  • Erste Asset Management's Intra-Cellular Therapies Inc. position peaked at $3.08M in Q1 2025.
  • 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Erste Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.